Smith D Scott
Stanford University School of Medicine, Redwood City, CA, USA.
Top Antivir Med. 2012 Aug-Sep;20(3):111-5.
For the purposes of vaccination, persons with asymptomatic HIV infection and CD4+ cell counts of 200/μL to 500/μL are considered to have limited immune deficits and are generally candidates for immunization. HIVinfected persons with CD4+ cell counts less than 200/μL or history of an AIDS-defining illness should not receive live-attenuated viral or bacterial vaccines because of the risk of serious systemic disease and suboptimal response to vaccination. Available data indicate that immunization during antiretroviral therapy restores vaccine immunogenicity, improves the rate and persistence of immune responses, and reduces risk of vaccine-related adverse events, although vaccine responses often are suboptimal. Major issues for travelers to the developing world are vaccine-preventable illnesses (hepatitis A virus, yellow fever, and typhoid fever), traveler's diarrhea, and malaria. This article summarizes a presentation by D. Scott Smith, MD, at the IAS-USA continuing medical education program held in San Francisco in April 2012.
就疫苗接种而言,无症状HIV感染者且CD4+细胞计数为200/μL至500/μL的人群被认为免疫缺陷有限,通常是疫苗接种的对象。CD4+细胞计数低于200/μL或有艾滋病界定疾病史的HIV感染者不应接种减毒活病毒或细菌疫苗,因为存在发生严重全身性疾病的风险以及对疫苗接种反应欠佳。现有数据表明,抗逆转录病毒治疗期间进行疫苗接种可恢复疫苗免疫原性,提高免疫反应的发生率和持续性,并降低疫苗相关不良事件的风险,尽管疫苗反应往往欠佳。前往发展中世界的旅行者面临的主要问题是疫苗可预防疾病(甲型肝炎病毒、黄热病和伤寒热)、旅行者腹泻和疟疾。本文总结了医学博士D. 斯科特·史密斯于2012年4月在旧金山举行的美国国际艾滋病学会继续医学教育项目上的一次演讲。